

# Big Data in OB and OB Anesthesia Research

Brian T. Bateman, MD, MSc  
Associate Professor of Anesthesia  
Department of Anesthesia, Critical Care, and Pain Medicine  
Massachusetts General Hospital  
Division of Pharmacoepidemiology and Pharmacoeconomics  
Department of Medicine  
Brigham and Women's Hospital  
Harvard Medical School

# Disclosures

- Research funding:
  - National Institutes of Health
  - Icelandic Centre for Research
  - Pfizer
  - Lilly
  - Baxalta
  - GSK
  - Pacira

# Outline


- Overview of research based on healthcare utilization data
  - Types of data sources
  - Types of research
- Methodological considerations in comparative effectiveness/ safety research
  - Example of statins and congenital malformations
- Novel methods to control for unmeasured confounders
  - Example of induction and the risk of autism

# Healthcare utilization data

- Routinely collected for the **payment** and **administration** of health services
  - **Claims** for services/procedures/medications
  - **Diagnoses** used to justify services
- **Not collected primarily for research purposes**



# Publications in obstetrics based on healthcare utilization data



# Advantages of healthcare utilization data

- **Large**
  - Rare events
  - Power to analyze subgroups
- **Representative**
  - Real-world effectiveness and utilization patterns
- **Informative regarding health systems**
  - Information on volume, hospital/physician characteristics, costs
- **Accessible**
  - Data are available at low cost
  - Near real-time

# Available data sources

- Types: Longitudinal and episodic
- Longitudinal databases
  - Claims for outpatient, inpatient, laboratory, imaging services, medication dispensing
- Examples:
  - Medicaid Analytic eXtract (MAX)
  - United Healthcare database
  - Kaiser Permanente



# Available data sources

- Episodic databases
- Information derived from single, inpatient encounter
- Examples:
  - Nationwide Inpatient Sample
    - 20% stratified-sample of all US hospitalizations
  - State Inpatient Databases
    - Complete claims for admissions from selected states
  - Premier Perspective Database
    - ~1/6 of all US hospitalizations; granular data on hospital charges

# Healthcare utilization data

- Types of studies:
  - Descriptive studies
    - Disease/complication epidemiology
    - Healthcare utilization
  - Disease/complication risk prediction
  - Comparative effectiveness/safety research

# Healthcare utilization data

- Types of studies:
  - Descriptive studies
    - Disease/complication epidemiology
    - Healthcare utilization
  - Disease/complication risk prediction
  - Comparative effectiveness/safety research

# Cardiac Arrest during Hospitalization for Delivery in the United States, 1998–2011

Jill M. Mhyre, M.D., Lawrence C. Tsen, M.D., Sharon Einav, M.D., Elena V. Kuklina, M.D., Ph.D.,  
Lisa R. Leffert, M.D., Brian T. Bateman, M.D., M.Sc.



# Cardiac Arrest during Hospitalization for Delivery in the United States, 1998–2011

Jill M. Mhyre, M.D., Lawrence C. Tsen, M.D., Sharon Einav, M.D., Elena V. Kuklina, M.D., Ph.D.,  
Lisa R. Leffert, M.D., Brian T. Bateman, M.D., M.Sc.



- Nationwide Inpatient Sample
- 56 million deliveries
- Frequency: 1 in 12,000
- Leading etiology: Hemorrhage (40%)
- Post-arrest survival: 58.9%



# Healthcare utilization data

- Types of studies:
  - Descriptive studies
    - Disease/complication epidemiology
    - Healthcare utilization
  - Disease/complication risk prediction
  - Comparative effectiveness/safety research

# **Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States**

Brian T. Bateman, M.D., M.Sc., Sonia Hernandez-Diaz, M.D., Dr.P.H., James P. Rathmell, M.D., John D. Seeger, Pharm.D., Dr.P.H., Michael Doherty, M.S., Michael A. Fischer, M.D., M.S., Krista F. Huybrechts, M.S., Ph.D.



# **Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States**


Brian T. Bateman, M.D., M.Sc., Sonia Hernandez-Diaz, M.D., Dr.P.H., James P. Rathmell, M.D., John D. Seeger, Pharm.D., Dr.P.H., Michael Doherty, M.S., Michael A. Fischer, M.D., M.S., Krista F. Huybrechts, M.S., Ph.D.



- United Healthcare
- 534,500 pregnancies from 2005 to 2011
- 14.4% opioid exposed during pregnancy
- Significant regional variation

# Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States

Brian T. Bateman, M.D., M.Sc., Sonia Hernandez-Diaz, M.D., Dr.P.H., James P. Rathmell, M.D., John D. Seeger, Pharm.D., Dr.P.H., Michael Doherty, M.S., Michael A. Fischer, M.D., M.S., Krista F. Huybrechts, M.S., Ph.D.



# Healthcare utilization data

- Types of studies:
  - Descriptive studies
    - Disease/complication epidemiology
    - Healthcare utilization
  - Disease/complication risk prediction
  - Comparative effectiveness/safety research

# Development of a Comorbidity Index for Use in Obstetric Patients

*Brian T. Bateman, MD, MSc, Jill M. Mhyre, MD, Sonia Hernandez-Diaz, MD, DrPH, Krista F. Huybrechts, MS, PhD, Michael A. Fischer, MD, MS, Andreea A. Creanga, MD, PhD, William M. Callaghan, MD, MPH, and Joshua J. Gagne, PharmD, ScD*





# Development of a Comorbidity Index for Use in Obstetric Patients

*Brian T. Bateman, MD, MSc, Jill M. Mhyre, MD, Sonia Hernandez-Diaz, MD, DrPH, Krista F. Huybrechts, MS, PhD, Michael A. Fischer, MD, MS, Andreea A. Creanga, MD, PhD, William M. Callaghan, MD, MPH, and Joshua J. Gagne, PharmD, ScD*



- Medicaid Analytic eXtract
- 854,823; 1.2% severe morbidity
- Includes 20 maternal conditions
- Risk=0.68% for score 0; 10.9% if >10

# Healthcare utilization data

- Types of studies:
  - Descriptive studies
    - Disease/complication epidemiology
    - Healthcare utilization
  - Disease/complication risk prediction
  - Comparative effectiveness/safety research



# Comparative effectiveness and safety research

- Gold standard → Randomized controlled clinical trials
  - Lack problem of confounding
  - May lack generalizability
  - Less useful in establishing safety
  - Limited follow-up time
  - Not all relevant questions will be answered with RCTs

# Comparative effectiveness and safety research

- Gold standard → Randomized controlled clinical trials
  - Lack problem of confounding
  - May lack generalizability
  - Less useful in establishing safety
  - Limited follow-up time
  - Not all relevant questions will be answered with RCTs


# Healthcare utilization data

- **Challenges**
- Those inherent to all observational research
  - Selection bias
  - Information bias
  - Confounding bias
- Those particular to healthcare utilization data
  - Strong potential for **misclassification/underascertainment** of outcomes, exposures, and confounders

# Study question



# Study question



# Challenges: Outcome misclassification

- Not as problematic as one might think...
- Important to define the outcome with specificity
  - If the outcome is defined with **100% specificity**, then **relative risk estimates** will be **unbiased** assuming that misclassification is non-differential

# The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100

## The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100



## The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100

$$RR = 2$$

## The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100

$$RR = 2$$


Outcome measured with 50% sensitivity

## The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100

$$RR = 2$$

## Outcome measured with 50% sensitivity




	Outcome	Total
Exposed	10	100
Unexposed	5	100

## The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100

$$RR = 2$$

## Outcome measured with 50% sensitivity




	Outcome	Total
Exposed	10	100
Unexposed	5	100

## The truth

	Outcome	Total
Exposed	20	100
Unexposed	10	100

$$RR = 2$$

## Outcome measured with 50% sensitivity



	Outcome	Total
Exposed	10	100
Unexposed	5	100

$$RR = 2$$

	Sensitivity (%)	Specificity (%)
<b>Obstetric hemorrhage</b>	75	99.8
<b>Episiotomy</b>	70	99.9
<b>Obstetric wound infection</b>	68	98
<b>Venous thromboembolism</b>	87	98
<b>Renal failure</b>	88	99.4
<b>Endometritis</b>	46	98
<b>Venous thromboembolism</b>	87	98

- Aronsky et al, *Am J Med Qual*, 2005;20:319-28
- Romano and Mark, *Med Care*, 1994; 32: 81-90
- Kiyota et al, *Am Heart J*, 2004; 148: 99-104
- Shaklee et al, *Infect Dis J* 2011;30:e38-40
- Li et al, *Pharmacoepidemiol Drug Saf.* 2011 Jul;20(7):700-8.
- Henderson et al, *Jt Comm J Qual Patient Saf.* 2009 Jul;35(7):370-6.
- Goff et al, *Paediatr Perinat Epidemiol.* 2012 Sep;26(5):421-9
- Romano et al, *Obstet Gynecol.* 2005;106(4):717-25.

# Challenges: Outcome misclassification

- Specificity further improved with treatment codes or LOS
  - Infection: Appropriate antibiotics
  - PPH: Transfusion
  - Severe preeclampsia: Magnesium
  - MI: LOS >3 days

# Challenges: Exposure misclassification

- Can often be measured with sensitivity and specificity
  - Charges for drugs, procedures
- When the exposure is a diagnosis, misclassification may create bias of effect estimates



# Challenges: Exposure misclassification

- Particularly problematic in episodic databases
  - **Overcoding:** Patient with peridelivery MI may have more codes for known risk factors than comparable patient without the complication
  - **Undercoding:** Patients that have a long and complicated hospital course may have fewer codes for chronic conditions
    - DM paradoxically appears to decrease the risk peridelivery sepsis in administrative datasets

# Challenges: Confounder underascertainment/misclassification

- Misclassification of or inability to measure confounders is the **greatest threat** to validity of studies using administrative data

# Challenges: Confounder underascertainment/ misclassification

- Minimize the degree of confounding at the design phase
  - Use of active comparators
- Use proxies to identify relevant comorbidities
  - Insulin → DM
  - Labetalol → HTN
  - Number of outpatient medications as a marker for general health status

# High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data

*Sebastian Schneeweiss, Jeremy A. Rassen, Robert J. Glynn, Jerry Avorn, Helen Mogun, and M. Alan Brookhart*

- Draws on range of data dimension including diagnoses, procedures, laboratory tests, and medications
- Empirically identifies candidate covariates from thousands of codes
- Prioritizes covariates, and integrates them into a propensity-score
- Improves confounding control in some circumstances

# Statins and congenital malformations



# Statins and congenital malformations

- Food and Drug Administration **Category X**
  - Animal data showing the potential for toxicity
  - Role of cholesterol biosynthesis for prenatal development
- Few human data
  - Mixed results
  - Registries, small cohort studies, and spontaneous reports
- Important:
  - Use in women of reproductive age
  - Potential use in preventing preeclampsia



OPEN ACCESS



## Statins and congenital malformations: cohort study

Brian T Bateman,<sup>1,2</sup> Sonia Hernandez-Diaz,<sup>3</sup> Michael A Fischer,<sup>1</sup> Ellen W Seely,<sup>4</sup>  
Jeffrey L Ecker,<sup>5</sup> Jessica M Franklin,<sup>1</sup> Rishi J Desai,<sup>1</sup> Cora Allen-Coleman,<sup>1</sup> Helen Mogun,<sup>1</sup>  
Jerry Avorn,<sup>1</sup> Krista F Huybrechts<sup>1</sup>

- Medicaid Analytic eXtract 2000-2007
  - N = 886,996
  - 1,152 (0.13%) statin exposed in 1<sup>st</sup> trimester
- Outcome → Congenital malformations
  - Defined by codes of 2 separate dates
  - One code + corrective surgery (**high specificity**)
- 50 covariates drawn from claims
  - Demographics, diagnoses, medications, healthcare utilization (**robust confounder control incld many proxies**)

# Statins and congenital malformations

	Risk	Unadjusted
<b>Unexposed</b>	3.55%	Referent
<b>Exposed</b>	6.34%	1.79 (1.43 to 2.23)



# Statins and congenital malformations

	Risk	Unadjusted	Stratified on diabetes
<b>Unexposed</b>	3.55%	Referent	Referent
<b>Exposed</b>	6.34%	1.79 (1.43 to 2.23)	1.34(1.07 to 1.68)

# Statins and congenital malformations

	Risk	Unadjusted	Stratified on diabetes	Propensity-score matched (1:3)*
<b>Unexposed</b>	3.55%	Referent	Referent	Referent
<b>Exposed</b>	6.34%	1.79 (1.43 to 2.23)	1.34(1.07 to 1.68)	1.04 (0.79 to 1.37)

# Novel design approaches to overcome residual confounding

- Circumstances where traditional designs are likely to result in residual confounding
- In this circumstance novel epidemiological designs are needed
- Example: Induction of labor and autism

# Background

## **Autism Spectrum Disorders (ASD):**

- Permanent developmental disabilities
  - Impairment in social interaction
  - Language development
  - Stereotyped or repetitive behaviors
  - Incidence: 1 in 90
- Genetics and early environmental exposures implicated in pathophysiology
  - Investigation of association with perinatal exposures

# Background

## **Oxytocin:**

- Key role in social function and cognition
- Used to induce/augment labor

## **Hypothesis:**

- *In-utero* exposure causes down-regulation of oxytocin receptors predisposing to ASD

Original Investigation

# Association of Autism With Induced or Augmented Childbirth in North Carolina Birth Record (1990-1998) and Education Research (1997-2007) Databases

Simon G. Gregory, PhD; Rebecca Anthopolos, MA; Claire E. Osgood, BS; Chad A. Grotegut, MD; Marie Lynn Miranda, PhD

*JAMA Pediatr.* 2013;167(10):959-966. doi:10.1001/jamapediatrics.2013.2904  
Published online August 12, 2013.

- Linked information on 625,042 births to educational records
  - Exposure: Induction
  - Outcome: Autism exceptionality designation
  - After adjustment for confounders:
    - Relative risk: 1.27 (95% CI 1.05-1.52)

## Induced Labor Linked to Raised Risk of Autism, Study Suggests

Male children seem to be most vulnerable, researchers report



Are You Guilty of These Gym Results

## Autism Might Be Linked With Inducing And Speeding Up Labor (STUDY)

AP

By LINDSEY TANNER

Posted: 08/12/2013 5:06 pm EDT | Updated: 08/12/2013 5:06 pm EDT



AUTISM

## Induced Labor Linked to Higher Autism Risk

By Alexandra Sifferlin @acsifferlin | Aug. 13, 2013 | 0



Search

## Brain changes of autism may begin in the womb

Liz Szabo, USA TODAY 6:54 p.m. EDT August 13, 2013



Sign in

News

Sport

Weather

Shop

## NEWS

Home | Video | World | US & Canada | UK | Business | Tech | Science

Health

## Induced labour 'linked to autism'

By a

## Study Links Inducing/Augmenting Labor with Modestly Higher Autism Risk

Related



By MICHELLE CASTILLO / CBS NEWS / August 12, 2013, 6:03 PM

## Induced labor may increase risk of autism in offspring



Search foxnews.com

DR MANNY'S NOTES

## Can inducing labor make your child autistic?

Forbes ▼

New Posts +17

Most Popular

Lists

Video

2 Free Issues of Forbes

Search

SIGN IN | SUBSCRIBE

on up | Connect f t in

HEALTH & WELLNESS

## Study Finds Link Between Induced Labor and Autism Diagnoses

Researchers Don't Suggest Any Change in Current Medical Practices



PHARMA & HEALTHCARE | 8/14/2013 @ 3:43PM | 45,810 views

## Autism Risk And Labor Induction: Is There A Link?



The American College of  
Obstetricians and Gynecologists  
WOMEN'S HEALTH CARE PHYSICIANS

# COMMITTEE OPINION

Number 597 • May 2014

## Committee on Obstetric Practice

*The Society for Maternal-Fetal Medicine endorses this document. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.*

- ACOG issued a Committee Opinion:
  - *“against a change in current guidance regarding counseling and indications for and methods of labor induction...”*
- Avoiding induction may lead to more stillbirth, cesareans, and adverse effects on maternal health



# Association of Labor Induction With Offspring Risk of Autism Spectrum Disorders

Anna Sara Oberg, PhD; Brian M. D'Onofrio, PhD; Martin E. Rickert, PhD; Sonia Hernandez-Diaz, DrPH; Jeffrey L. Ecker, MD; Catarina Almqvist, PhD; Henrik Larsson, PhD; Paul Lichtenstein, PhD; Brian T. Bateman, MD

- A significant concern regarding prior study is potential for residual confounding
- Use Swedish nationwide population register data to identify differentially exposed siblings

# Methods

## **Study Population:**

- Births in Sweden 1992 to 2001
- N=978,98

## **Exposure:**

- Induction indicator on standardized delivery chart

## **Outcome:**

- Diagnoses of Autism Spectrum Disorder
- 1.1%

# Methods

## **Analysis:**

- Association between induction and ASD modelled using Cox proportional hazard regression

## • **Models:**

- Model 1: Baseline
- Model 2: Stable maternal characteristics:  
Demographics
- Model 3: Model 2+ individual birth characteristics:  
Risk factors for induction like postdates,  
preeclampsia, etc

# Methods

## **Model 4:**

- Fixed effects model in which the underlying hazard is allowed to vary between mothers (=fixed for all births to same woman)
- Contrast is made within siblings
  - Only siblings discordant with respect to induction status contribute to the estimation of effect
- Maintain adjustment for factors unique to each birth
- Controls for all factors shared by siblings

# Results

Baseline	
HR (95% CI)	
Autism spectrum disorders	1.27 (1.19 - 1.37)

# Results

	Baseline	Stable maternal
	HR (95% CI)	HR (95% CI)
Autism spectrum disorders	1.27 (1.19 - 1.37)	1.27 (1.18 - 1.36)

# Results

	Baseline	Stable maternal
	HR (95% CI)	HR (95% CI)
Autism spectrum disorders	1.27 (1.19 - 1.37)	1.27 (1.18 - 1.36)

# Results

	Baseline	Stable maternal	Individual birth
	HR (95% CI)	HR (95% CI)	HR (95% CI)
Autism spectrum disorders	1.27 (1.19 - 1.37)	1.27 (1.18 - 1.36)	1.18 (1.09 - 1.27)



# Results

	Baseline	Stable maternal	Individual birth	Within siblings
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Autism spectrum disorders	1.27 (1.19 - 1.37)	1.27 (1.18 - 1.36)	1.18 (1.09 - 1.27)	1.05 (0.87 - 1.27)

# Conclusions

- Big data are a powerful tool for research in OB and OB anesthesia
- Attention to study design and limitations of data needed
- Novel approaches can help minimize the risk for residual confounding and yield valid estimates

